Precision BioSciences Inc. (NASDAQ:DTIL) presented new preclinical findings for its PBGENE-DMD gene therapy at the Muscular ...

Barclays 28th Annual Global Healthcare Conference March 12, 2026 11:30 AM EDTCompany ParticipantsAlexander Cumbo - ...

Non-alcoholic fatty liver disease (NAFLD) impacts millions globally, often advancing silently while elevating the challenge of metabolic disorders. While medications can aid in controlling some health ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

NMN抗衰、NMN补充NAD+、NMN安全性……随着“抗衰”成为全民健康关键词，NMN(β-烟酰胺单核苷酸)作为NAD+的直接前体，热度持续 ...

Detailed price information for Alaunos Therapeutics Inc (TCRT-Q) from The Globe and Mail including charting and trades.

CAPE CANAVERAL SPACE FORCE STATION — For those who woke up early on Thursday morning, they got to see SpaceX launch AST SpaceMobile’s five commercial satellites despite the weather not looking ...

Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment. For oncology clinicians, the Liver Imaging-Reporting and Data System ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in people ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority?owned subsidiary of Citius ...